Genetic Determinants of Hemodynamic Response to Esmolol
NCT ID: NCT01388036
Last Updated: 2011-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients
NCT02188888
Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion
NCT04181606
The Hemodynamic Response to Prolonged Dobutamine Infusion
NCT01042873
Analysis of Atropine and Propranolol Induced Changes
NCT00251602
Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms
NCT00226551
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
esmolol infusion
infusion of esmolol during rest and exercise
esmolol
consecutive infusions of esmolol and normal saline (placebo)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
esmolol
consecutive infusions of esmolol and normal saline (placebo)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to understand and sign informed consent
Exclusion Criteria
* bradycardia \<50 BPM
* hypersensitivity to beta blockers
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hadassah- Hebrew University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Hebrew University Medical Center
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Muszkat M, Hoofien A, Orlanski-Meyer E, Makhoul H, Porat E, Davidson EM, Blotnick S, Caraco Y. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting beta(1) adrenergic receptor antagonist esmolol in healthy individuals. Pharmacogenet Genomics. 2013 Jan;23(1):25-8. doi: 10.1097/FPC.0b013e32835afde6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
397-27.05.05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.